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Abstract
Background Periodic paralysis (PP) is a rare genetic disorder in which ion channel mutation causes episodic paralysis
in association with hyper- or hypokalaemia. An unexplained but consistent feature of PP is that a phenotype transition
occurs around the age of 40, in which the severity of potassium-induced muscle weakness declines but onset of fixed,
progressive weakness is reported. This phenotype transition coincides with the age at which muscle mass and optimal
motor function start to decline in healthy individuals. We sought to determine if the phenotype transition in PP is linked
to the normal ageing phenotype transition and to explore the mechanisms involved.
Methods A mouse model of hyperkalaemic PP was compared with wild-type littermates across a range of ages
(13–104 weeks). Only male mice were used as penetrance is incomplete in females. We adapted the muscle velocity
recovery cycle technique from humans to examine murine muscle excitability in vivo. We then examined changes in
potassium-induced weakness or caffeine contracture force with age using ex vivo muscle tension testing. Muscles
were further characterized by either Western blot, histology or energy charge measurement. For normally distributed
data, a student’s t-test (± Welch correction) or one- or two-way analysis of variance (ANOVA) was performed to de-
termine significance. For data that were not normally distributed, Welch rank test, Mann Whitney U test or Kruskal–
Wallis ANOVA was performed. When an ANOVA was significant (P < 0.05), post hoc Tukey testing was used.
Results Both WT (P = 0.009) and PP (P = 0.007) muscles exhibit increased resistance to potassium-induced weak-
ness with age. Our data suggest that healthy-old muscle develops mechanisms to maintain force despite sarcolemmal
depolarization and sodium channel inactivation. In contrast, reduced caffeine contracture force (P= 0.00005), skeletal
muscle energy charge (P = 0.004) and structural core pathology (P = 0.005) were specific to Draggen muscle, indicat-
ing that they are caused, or at least accelerated by, chronic genetic ion channel dysfunction.
Conclusions The phenotype transition with age is replicated in a mouse model of PP. Intrinsic muscle ageing protects
against potassium-induced weakness in HyperPP mice. However, it also appears to accelerate impairment of sarcoplas-
mic reticulum calcium release, mitochondrial impairment and the development of core-like regions, suggesting ac-
quired RyR1 dysfunction as the potential aetiology. This work provides a first description of mechanisms involved in
phenotype transition with age in PP. It also demonstrates how studying phenotype transition with age in monogenic
disease can yield novel insights into both disease physiology and the ageing process itself.
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Introduction
The skeletal muscle channelopathies are a group of disorders
whose manifestations range from flaccid paralysis to myoto-
nia: They are broadly divided into the periodic paralyses
(PP) and the non-dystrophic myotonias.1 The PP include
hyperkalaemic PP (HyperPP), hypokalaemic PP (HypoPP) and
Andersen–Tawil syndrome. All these conditions are caused
by dominant mutations in skeletal muscle ion channels that
predispose to prolonged depolarization of the muscle mem-
brane. In some circumstances, this increases the propensity
to activate voltage-gated sodium channels and trigger action
potentials, resulting in a hyperexcitable membrane that clin-
ically manifests as myotonia. However, regardless of the pres-
ence of preceding hyperexcitability, excessive depolarization
can lead to inactivation of both normal and mutant sodium
channels, rendering the muscle inexcitable.2,3 This manifests
as episodes of PP that usually occur in association with high
or low serum potassium.1
In patients with PP, early in the disease course, muscle
strength is reported to be normal in-between attacks of
paralysis. However, an unexplained but consistent clinical
feature is that around the age of 40, a second clinical phase
is observed, in which attack severity declines and severe,
fixed and often disabling weakness develops.4–9 It is unclear
why dysfunction of implicated ion channels exhibits this
biphasic natural history.
It is notable that in addition to being the age of phenotypic
shift in PP patients, 40 is also the age at which even in healthy
adults, optimal motor performance begins to decline,10
muscle mass decreases,11 grip strength reduces12 and mito-
chondrial abnormalities begin to be accepted as within the
normal range for age on muscle biopsy.13 This suggests the
possibility that age-related change may contribute to the phe-
notype transition in PP.
The Draggen mouse model of HyperPP carries an SCN4A
gain-of-function mutation (I582V) in the skeletal muscle
voltage-gated sodium channel (Nav1.4), equivalent to that
found in a patient with PP and myotonia (I588V).14 This muta-
tion is located within the S1 segment of the second domain of
NaV1.4. Heterozygote Draggen mice exhibit episodic attacks
of hindlimb dragging, the number and severity of which can
be very variable. However, an attack of weakness can be reli-
ably induced ex vivo by exposure of Draggen muscle to a
high-potassium solution.14 The heterozygote Draggen mice
also reproduce onset of fixed weakness with a progressive
decline in grip strength from middle age as well as classic
histological features of PP myopathy on muscle biopsy.14
Therefore, in this study, Draggen mice were used to charac-
terize changes in ageing muscle and compared with ‘normal’




Male heterozygous Draggen mice (three generations of back-
cross onto C57Bl/6J)14 were bred with C57/BL 6J female mice.
Only male mice were used in these studies as there is incom-
plete penetrance in females.14 Mice were fed ad libitum and
housed according to home office guidelines. All experiments
were performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later amend-
ments. Experiments were carried out under licence from the
UK Home Office (Scientific Procedures Act 1986) and follow-
ing approval by the UCL Institute of Neurology Animal Wel-
fare Ethical Review Panel. Some animals had a plastic flying
saucer running wheel added to their cage from middle age
to assess the effects of voluntary exercise on age-related loss
of muscle mass. Data from this group of animals were only
included in the analysis of histology (Figure 6) and weight
(Figure 7). In both cases, the values obtained from animals
with access to a running wheel are given and are compared
with values from data from animals without access to a
running wheel.
Experimental protocol
In vivo muscle velocity recovery cycles (MVRCs) and fre-
quency ramp recordings were performed under terminal
isoflurane anaesthesia on triceps brachii and tibialis anterior
(TA) muscles bilaterally and were followed by dissection of
TA and soleus or gastrosoleus. TA was then used for assess-
ment of weight and adenylate energy charge. Soleus was
used for functional testing (muscle tension testing followed
by caffeine contracture or the potassium-induced weakness
assay), for Western blot or (when combined with gastrocne-
mius) for histological analysis.
MVRCs were not technically possible in soleus as it is a
deep, thin muscle, and therefore, in a live and intact animal,
we could not be certain we were recording from soleus. We
chose TA for MVRCs as it is easily accessible and has been
shown to develop the characteristic histological features of
PP myopathy in aged Draggen mice.14 The mouse TA is
composed predominantly (90%) of fast myofibres (Types 2X
and 2B) compared with soleus that is ~90% slow myofibres
(Types 1 and 2A).15 It was not possible to perform the
potassium-induced weakness assay in TA as it cannot be iso-
lated with both tendons intact and therefore is not suitable
for ex vivo muscle tension measurement.
We chose soleus for the ex vivo potassium-induced weak-
ness assay for several reasons. Firstly, this is because soleus
is the mouse muscle that is most similar to human skeletal
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muscle in terms of gene expression and fibre-typing.16
Secondly, this is because it is more susceptible to
potassium-induced weakness than the other muscle well
suited to ex vivo muscle tension measurements, fast-twitch
glycolytic extensor digitorum longus.17 Thirdly, as HyperPP
mouse muscle is known to switch towards a more oxidative
fibre type from around 12 weeks of age14,18 and this may
alter sensitivity to potassium-induced weakness,16 we chose
a muscle that is already oxidative to reduce any potential
contribution of fibre-type transformation.
MVRCs and frequency ramp recordings in vivo
Isoflurane anaesthesia was induced in an anaesthetic
chamber. After induction, the mouse was placed on its back
on a heat mat and anaesthesia maintained via a nose cone
(Figure S1). As MVRCs have not been reported in rodents,
they were performed as described previously for
humans.19–22 Recordings were performed in vivo on either
TA (Figure S1A) or triceps (Figure S1B). The signal was am-
plified (gain 1000, bandwidth 50 Hz to 2 kHz) and digitized
(NI DAQ) using a sampling rate of 20 kHz. The electrodes
were adjusted to obtain a stable negative peak response
with a stimulus of 3–10 mA. Stimulation and recording were
controlled by QTRAC software using the M3REC3.QRP pro-
tocol. Surface temperature over the muscle was measured
at the end of the recording either using an infrared ther-
mometer or by applying a glass thermometer to the skin
overlying the muscle. MVRCs were recorded with 1, 2 and
5 conditioning stimuli all separated by 10-ms intervals. Test
stimuli were delivered every 2 s. The inter-stimulus interval
between the last conditioning stimulus and the test stimulus
varied from 1000 to 1.4 ms in 34 steps in an approximately
geometric series (specifically 1000, 900, 800, 700, 600, 500,
450, 400, 350, 300, 260, 220, 180, 140, 110, 89, 71, 56, 45,
35, 28, 22, 18, 14, 11, 8.9, 7.1, 5.6, 4.5, 3.5, 2.8, 2.2, 1.8 and
1.4 ms).19
A 30-Hz frequency ramp was performed as described for
humans19 as it has not been reported for mice previously.
Figure 1 Normal muscle. Skeletal muscle excitability involves the initiation of an action potential at the neuromuscular junction (not shown) and sub-
sequent propagation of an action potential along the sarcolemma and into the T-tubules. Muscle velocity recovery cycles (MVRCs) and frequency ramp
provide an indirect measurement of muscle excitability by examining changes in conduction velocity. Excitation–contraction coupling links muscle ex-
citability to muscle contraction and requires depolarization of the T-tubule voltage-gated calcium channel (CaV1.1, yellow). Activation of CaV1.1 phys-
ically activates the sarcoplasmic reticulum (SR) calcium release channel (RyR1, grey), a process known as excitation–contraction coupling. Caffeine
application bypasses excitability to act on RyR1 directly. Calcium released through RyR1 not only triggers calcium-induced muscle contraction but also
stimulates mitochondrial ATP synthesis. The energy charge is the ratio of ATP to ADP and AMP and reflects the metabolic status of the tissue. ATP is
critical for ionic homeostasis, for example, to maintain skeletal muscle resting membrane potential via the Na⁺/K⁺-ATPase (green and yellow stripes)
and SR calcium stores via the SR Ca
2+
ATPase (grey and green stripes). ATP is also critical for myosin–actin cross-bridge cycling.
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The test stimulus was preceded by a 1 second train of stimuli
at a frequency that was increased by 1 Hz on successive 2-s
cycles from 1 to 30 Hz. The average stimulation rate was
therefore increased from 0.5 to 15.5 Hz over 1 min. Stimulus
cycles with the test stimulus alone were recorded before (10
cycles at 0.5 Hz), during the ramp and for a further 30 s after
the end of the ramp.19
Muscle force measurements on soleus muscle
ex vivo
The soleus muscle was dissected while the mouse remained
under isoflurane anaesthesia and placed in the centre well
of a three-well custom-made chamber designed by Scientific
Systems Design Inc. and purchased via Digitimer. The two
side wells were used to pre-oxygenate and warm exchange
solutions prior to application. Fluid in all three chambers
was maintained at 30°C (as this was the temperature re-
corded from the surface of exposed soleus in situ using an
infrared thermometer) and continuously bubbled with 95%
O2, 5% CO2. The proximal muscle tendon was tied to a steel
bar within the muscle chamber, and the distal tendon was
tied to an isometric force transducer (Dynamometer UFI
Devices). Tetanic stimuli (200-ms train duration) were
delivered using square wave pulses at supramaximal inten-
sity applied via platinum wires positioned either side of
the muscle. Muscles were adjusted to their optimal preload
length to produce maximal tetanic contraction. Isometric
contractile responses were recorded using a pen recorder
(Lectromed MultiTrace 2) and digitized with PicoScope PC
Oscilloscope 4424.
The potassium-induced weakness assay was performed as
described previously for the M1592V HyperPP mouse model,
with concomitant changes in calcium included as this exacer-
bates the difference between mutant and WT mice.17,18,23,24
The baseline bath solution contained NaCl 118 mmol; KCl
4.75 mmol; MgSO4 1.18 mmol; CaCl2 2.54 mmol; NaH2PO4
1.18 mmol; glucose 10 mmol; NaHCO3 24.8 mmol. The
high-potassium, low-calcium solution differed from the base-
line bath solution as follows: NaCl 113 mmol; KCl 10 mmol;
MgCl2 1.04 mmol; CaCl2 1.3 mmol. The high-calcium recovery
solution contained the same as the baseline solution except
CaCl2 was increased to 4 mmol. Muscles were not exposed
to insulin or curare. The potassium-induced weakness assay
was only performed in muscles that had 10 min of stable
(within 1 g) baseline force measurements. Tetanic force was
measured by 50 V stimulation at 100 Hz (train duration
200 ms) every 2 min during baseline and high-potassium
solutions and at 2, 5, 10, 15 and 20 min during high-calcium
recovery solution.
To look for evidence of excitation–contraction uncoupling,
caffeine contracture and tetanic force were examined as
described previously.25 The force elicited from exposure to
50 mM caffeine was compared with the baseline tetanic force
measured prior to caffeine application.
PicoScope 6 software was used to store and analyse the
data. Muscles that had a baseline maximal tetanic force that
was significantly weaker (>35% difference) than the contra-
lateral muscle exposed to the same conditions were excluded
as likely artefactual recordings secondary to injury. Muscles
that had a caffeine contracture force/tetanic force ratio of
>40% were excluded as this is associated with eccentric
injury.25
Histology
Soleus muscles from young, middle-aged and old (age range
13–103 weeks) adult male WT and Draggen mice were dis-
sected in combination with gastrocnemius under isoflurane
anaesthesia, snap-frozen in isopentane, and 10-μm sections
were cut in a cryostat. Sections were stained using
haemotoxylin and eosin (H&E), cytochrome oxidase (COX)
and succinate dehydrogenase (SDH) using standard
protocols.26 Semi-quantitative analysis of soleus was per-
formed, assessing structural pathology, COX-negative fibres
and fibre typing, while blinded to animal age and genotype.
Cores were defined light microscopically as lesions within
myofibres characterized by loss of oxidative staining.27
Immunoblot analysis to quantify protein levels
Soleus muscles were dissected and immediately flash-frozen.
To extract proteins, muscles were placed in lysis buffer [7 mL
of sample buffer (Tris HCl 75 mM, pH 6.8, SDS 1%) and one
tablet of Roche Complete Mini Protease inhibitor
(14583920) in lysing matrix M tubes (MPBio)]. Samples were
homogenized using the MP FastPrep-24 homogenizer, spun
at 4°C for 10 min at 10,000 rpm, and concentrations deter-
mined using Bio-Rad DC protein quantification assay. Samples
(20 μg sample protein diluted to make a total volume of
20 μL) were run for 2 h at 4°C on NuPAGE Tris-Acetate 3–
8% gels followed by wet transfer at 30 V for 5–6 h at 4°C onto
a nitrocellulose membrane. Following transfer, membranes
were stained with Ponceau to measure total protein. Mem-
brane was incubated in TBS with 10% milk overnight at 4°C,
then incubated with anti-RyR1 (abcam 2868) diluted 1:1000
in TBST (TBS with 0.05% Tween20) for 1 h at room tempera-
ture and then washed three times for 10 min in TBST before
incubation with an HRP conjugated secondary antibody at a
dilution of 1:4000 (Santa Cruz sc-2005#A2216 goat anti-
mouse) for 1 h at room temperature. After secondary
antibody incubation, membranes were washed three times
in TBS for 10 min and images taken using ChemiDoc MP
imager.
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Energy charge measured by high-pressure liquid
chromatography
To extract the adenine nucleotides, TA muscle samples that
had been immediately flash-frozen in liquid nitrogen follow-
ing dissection were weighed and homogenized in 0.5 mL
ice-cold 1.0 M perchloric acid, 250 μL of the homogenate
was neutralized with 200 μL 0.5 M KHCO3 in 1 M KOH.
The precipitated proteins and potassium perchlorate pro-
duced were removed by centrifugation at 13.000× g for
5 min, and the clear supernatants stored at 20°C until de-
rivatization. 100 μL of 1.0 M sodium acetate (pH 4.5) and
20 μL 4 M chloroacetaldehyde were mixed with 100 μL of
the neutralized extract and heated at 60°C for 40 min. After
the incubation, samples were placed on ice for 5 min to
cool and halt the reaction. Subsequently, 20 μL of the
cooled derivatized sample was analysed by high-pressure
liquid chromatography (HPLC) using a C18 reversed-phase
column (Hypersil 5 ODS 4.6 × 150 mm, 3 μm) at a flow rate
of 0.8 mL/min using a gradient from 100% 0.2 M KH2PO4,
pH 5.0 to 98.9% 0.2 M KH2PO4, pH 5.0 1.1% acetonitrile
over 31 min. Ethenoadenine nucleotides were determined
by fluorescence detection at excitation/emission spectra
pairs of 290ex/415em nm.
28 Peaks corresponding to the
retention times for ATP, ADP and AMP were integrated,
and peak areas obtained were used to calculate AEC using
the equation
AEC ¼ ATP½  þ 0:5 ADP½ ð Þ∕ ATP½  þ ADP½  þ AMP½ ð Þ
Statistics
Firstly, a normality test was performed. Where there were
two groups for comparison that passed the normality test, a
student’s t-test was performed. This was usually with Welch
correction as there were often differences in group size.
When there were two groups and for one or more normality
was rejected, either Welch rank test (MVRC or frequency
ramp data) or Mann–Whitney U test (other data) was
performed.
For three or more groups, when the primary question was
whether a significant difference between groups and not in-
teraction between factors was present, either a one-way
analysis of variance (ANOVA) or a Kruskal–Wallis ANOVA
was performed depending on normality. Post hoc Tukey test-
ing was performed when the ANOVA result was significantly
different (P = <0.05 unless otherwise specified). If the pri-
mary question was whether there was interaction between
factors, a two-way ANOVA was performed.
Finally, when categorical data were classified in two differ-
ent ways (e.g. specific histological feature observed on histol-
ogy of either Draggen or WT muscle), a two tailed Fisher’s
exact test was used (http://vassarstats.net/) to examine the
significance of any association between the two kinds of
classification.
All data are represented as mean ± standard error of the
mean (SEM) unless otherwise stated. As MVRCs and fre-
quency ramp analysis involve examining multiple parameters
simultaneously, an increased threshold for statistical signifi-
cance of P < 0.01 was applied.
Results
Resistance to potassium-induced weakness and
onset of fixed weakness occurs in Draggen mice
with age
Isolated soleus muscles from young (13–26 weeks),
middle-aged (55–75 weeks) and old (95–104 weeks) WT
(C57Bl/6J) mice and their Draggen littermates were used. A
significantly larger reduction in muscle force occurred during
the potassium-induced weakness assay in Draggen compared
with WT muscle in all age groups (P = 0.00005; Figure 2A and
2B). This was as described previously for 60-week-old Draggen
EDL.14
There were no significant differences between young and
middle-aged groups for WT or Draggen mice. However, mus-
cles from both old WT (P = 0.009) and old Draggen (P = 0.007)
mice were significantly more resistant to potassium-induced
weakness than their respective groups of young and
middle-aged mice (Figure 2A, P = 0.01 old vs. young WT,
P = 0.02 old vs. middle-aged WT; Figure 2B, P = 0.02 old vs.
young Draggen, 0.01 old vs. middle-aged Draggen). Whereas
old WT mice maintained force throughout exposure to the
high-potassium solution (Figure 2A), old Draggen muscle still
lost force but to a lesser degree than young or middle-aged
Draggen muscle (Figure 2B). The data were consistent for
muscles with a range of baseline force (Figure 2C and 2D).
In addition, it was noted that although force recovered fully
in the Draggen mice following return to the recovery solu-
tion, the recovery was incomplete in WT mice (end of assay
force  baseline force = 4.3 ± 1.7 g WT vs.  0.1 ± 1.5 g
Draggen, P = 0.01). In fact, old WT soleus actually lost force
during exposure to the recovery solution, whereas young
and middle-aged WT muscle showed incomplete recovery
(Figure 2A) as has been observed previously.18
A decline in grip strength from middle age has been previ-
ously reported in Draggen mice, but soleus tetanic force was
not measured.14 We found that there was a significant
decline in Draggen soleus tetanic force with age (P = 0.03) al-
though the rate of this decline did not differ from WT.
However, the intercept of linear fits to force-age data were
significantly different between Draggen and WT soleus,
suggesting reduced ex vivo force in young adult Draggen
Ageing and phenotype transition in periodic paralysis 249
JCSM Rapid Communications 2021; 4: 245–259
DOI: 10.1002/rco2.41
compared with WT soleus. Thus, Draggen mice showed
reduced force compared with WT mice at baseline and in re-
sponse to the potassium challenge, but both Draggen and WT
mice showed increased resistance to potassium challenge
with age.
Changes in muscle excitability with age
MVRCs use changes in skeletal muscle conduction velocity to
give an indirect measure of muscle excitability.22 They have
been performed in humans and pigs but have not previously
been reported in mice.22,29 We performed MVRCs on TA and
triceps muscles of WT and Draggen mice at the same three
ages as in Figure 2.
There were significant differences in MVRCs between WT
and Draggen mice at all ages (Supporting Information). MVRC
data suggest that Draggen TA is depolarized relative to WT TA
as the muscle relative refractory period is significantly longer
(Supporting Information). This is consistent with microelec-
trode findings from the M1592V HyperPP muscle demon-
strating depolarization relative to WT.17 Thus, MVRCs are
sensitive enough to detect changes in skeletal muscle
excitability and ion channel function in mice. However,
despite this, there were no significant differences in MVRCs
with age for either TA or triceps in WT or Draggen mice
(Figure 3). The fact that muscles of all ages respond similarly
to single or multiple pre-pulse stimulations suggests that
both the potassium accumulation and the response to
moderate activity-induced potassium accumulation remain
relatively constant throughout the life course.
Trains of action potentials increase the potassium concen-
tration in the T-tubules and around the muscle, and longer
trains cause a greater increase in potassium.30 If the resis-
tance to potassium-induced weakness in old mice is because
of resistance to potassium-induced depolarization, then the
amplitude of response should be better maintained during
longer trains of action potentials in old compared with
young or middle-aged mice. However, rather than better
maintenance of the amplitude of response, old WT TA had
a significantly greater decrement in response to the first
(P = 0.002) and last stimulus (P = 0.001) in a 30-Hz train
compared with younger WT muscle (Figure 4A). The decre-
ment in amplitude of response in old WT mice was accom-
panied by a progressive increase in latency (Figure 4A)
(slowing of conduction velocity), suggesting progressive
depolarization and inactivation of NaV1.4 channels. The am-
plitude of response in old WT TA also failed to return to
Figure 2 Changes in potassium-induced weakness and muscle force with age. (A) Potassium-induced weakness assay for young (black, n = 5) vs. mid-
dle-aged (blue, n = 4) vs. old (red, n = 5) WT soleus muscles. (B) Potassium-induced weakness assay for young (grey, n = 5) vs. middle-aged (light blue,
n = 5) vs. old (light red, n = 8) Draggen soleus muscles. (C) Absolute tetanic force at baseline and after 20-min exposure to high-potassium solution.
Results are from individual young (YW), middle-aged (MW) and old (OW) WT soleus. (D) Absolute tetanic force at baseline and after 20-min exposure
to high-potassium solution. Results are from individual young (YD), middle-aged (MD) and old (OD) Draggen soleus. (E) WT and Draggen soleus base-
line tetanic force according to age (up to 104 weeks). *P < 0.05, **P < 0.01.
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baseline and was significantly smaller as a percentage of its
baseline 30 s after the ramp than middle-aged WT TA
(P = 0.000008) (Figure 4A). There were no significant differ-
ences in the ramp recordings between young, middle-aged
and old Draggen TA (Figure 4B). There were also no signifi-
cant differences in ramp recordings with age for WT triceps
or between young and old Draggen triceps (Supporting
Information).
Figure 3 Muscle velocity recovery cycles (MVRCs) in TA and triceps muscles for WT and Draggen mice at three ages. (A) WT TA MVRCs in response to
one conditioning stimulus. (B) WT TA MVRCs in response to five conditioning stimuli. (C) Draggen TA MVRCs in response to one conditioning stimulus.
(D) Draggen TA MVRCs in response to five conditioning stimuli. (E) WT triceps MVRCs in response to one conditioning stimulus. (F) WT triceps MVRCs
in response to five conditioning stimuli. (G) Draggen triceps MVRCs in response to one conditioning stimulus. (H) Draggen triceps MVRCs in response to
five conditioning stimuli. WT TA young, n = 25; middle-aged, n = 17, old, n = 17. Draggen TA young, n = 15; middle-aged, n = 12 old, n = 12. WT triceps
young, n = 23; middle-aged, n = 6, old, n = 13. Draggen triceps young, n = 14; middle-aged, n = 3, old, n = 10. Black = young, blue = middle-aged,
red = old. n = number of individual muscles per group.
Figure 4 Response of WT and Draggen TA to in vivo 30-Hz frequency ramp by age. (A) Response of WT TA to 30-Hz frequency ramp. Young (black,
n = 22), middle-aged (blue, n = 13) and old (red, n = 14) mice. (B) Response of Draggen TA to 30-Hz frequency ramp. Young (grey, n = 15), middle-aged
(light blue, n = 8) and old (light red, n = 9) mice. The change in latency (time from stimulus to peak of response) is plotted on the top row as a per-
centage change from baseline latency. The change in amplitude of response is plotted on the middle row as a percentage change from baseline am-
plitude of response. During the frequency ramp (shown on bottom row), the percentage change in response to both the first and last stimuli in the
train are shown. The baseline is the mean latency and amplitude of response during the period of 0.5-Hz stimulation that precedes the frequency
ramp. ***P < 0.005, ****P < 0.0001.
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Caffeine contracture force is significantly reduced
in old Draggen soleus
Parameters controlling MVRCs do not appear to change with
age (Figure 3). Moreover, although old WT TA exhibits a re-
duction in the amplitude of response during high-frequency
stimulation (Figure 4), old Draggen TA does not. This sug-
gests that changes in parameters that lead to a reduction
in frequency ramp response amplitude are not the cause
for the fixed progressive weakness in Draggen muscle. As
parameters controlling muscle excitability (in MVRCs) do
not change significantly with age, the aetiology of the fixed
progressive weakness in Draggen mice is likely to lie down-
stream of muscle excitability. To investigate excitation–
contraction coupling, we studied excitation–contraction
coupling using caffeine contracture force ex vivo. Caffeine
bypasses muscle excitability and acts directly on ryanodine
receptors (RyR1) to cause calcium release and muscle con-
traction (Figure 1).
Caffeine contracture force was significantly reduced with
age in Draggen but not WT soleus (P = 0.00005) (Figure 5A).
There was also a trend (P = 0.09) towards a reduction in the
ratio between caffeine contracture force and tetanic force
ex vivo in old Draggen soleus (Figure 5B). An increase in this
ratio would be expected in the event of failure of CaV1.1 to
activate RyR1 (excitation–contraction uncoupling). Therefore,
the reduced caffeine contracture of old Draggen muscle
suggests impairment of RyR1 Ca2+ release, SR Ca2+ storage
or Ca2+-induced muscle contraction but not excitation–
contraction uncoupling.
Figure 5 Caffeine contracture force of adult and old WT and Draggen soleus. (A) Caffeine contracture force compared for WT and Draggen mice at two
ages: adult (13–42 weeks) and old (91–103 weeks). Individual data points are shown. (B) The ratio of caffeine contracture to tetanic force is compared
for WT and Draggen mice at the same two ages as (A). Individual data points are shown. (C) Ponceau to compare total protein and Western blot to
measure RyR1 expression in adult and old Draggen soleus (Abcam 2868 1:1000) AD = adult Draggen (18–68 weeks), OD = old Draggen (99–100 weeks);
****P < 0.001.
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A reduction in RyR1 expression is one possible cause of re-
duced caffeine contracture force. However, band thickness
on Western blots comparing adult (13–42 weeks, n = 4) and
old (91–103 weeks, n = 4) Draggen soleus suggests that
RyR1 protein levels were similar (Figure 5C). This is in keeping
with the reported lack of age-related change in healthy mus-
cle RyR1 expression in humans31,32 and mice.33 This suggests
that functional impairment in RyR1 calcium release rather
than reduced levels of RyR1 protein accounts for the reduced
caffeine contracture force in old Draggen soleus.
Structural core pathology is prevalent in the muscle
of Draggen mice
Cores and mini-cores are seen in patients with myopathies
due to mutation of RyR1. One of 10 WT soleus examined
(age range 27–103 weeks, mean age 78 weeks) and 11 of
the 16 Draggen soleus examined (age range 13–103 weeks,
mean age 66 weeks) had cores and core-like regions
(P = 0.005, two-tailed fisher exact test) (Figure 6). This in-
cluded animals with (n = 7 Draggen, n = 5 WT) and without
(n = 8 WT, n = 9 Draggen) access to a voluntary running
wheel.
The only WT animal with core pathology was a 62-week-
old animal that did not have access to a voluntary running
wheel. Six of 9 Draggen mice that did not have access to a
voluntary running wheel had cores compared with five of
seven Draggen mice with access to a voluntary running
wheel. In those without access to a voluntary running wheel,
cores were not seen in the youngest two animals (13 and
14 weeks) but were seen in a 27-week-old animal. In those
with access to a voluntary running wheel, two of the three
middle-aged animals did not have cores, whereas all old
Figure 6 Soleus muscle pathology in young and ageing wild-type and Draggen mice. Young wild-type mouse (A–C). Young Draggen mouse (D–F). Ageing
wild-typemouse (G–I). Ageing Draggenmouse (J–L). Sections stained with NADH-TR (A,B,D,E,G,H,J,K) and COX-SDH (G,F,I,L). Scanningmagnification view
(A,D,G,J) in all animals shows a transverse section through themid-belly of the gastrocnemius–soleus muscle. The smaller oxidative, Type I fibre predom-
inant soleus (circle) is present under the larger mixed-fibre-type gastrocnemius. In the young wild-type (B,C) and young Draggen (E,F), the muscle archi-
tecture is normal. In the agedwild-typemouse (H,I), there is subtle uneven oxidative staining in a proportion of fibres, but no overt pathology. In contrast,
in the aged Draggen mouse (K,L), both show florid core pathology affecting several fibres, ranging from marked unevenness of oxidative staining,
multicores, discrete small cores and occasionally well-defined larger cores (K,L, arrow). Scale bar: A, D, G, J = 1mm;N = 50 μm; B, C, E, F, H, I, K, L = 100 μm.
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animals did. When combined, the average age of Draggen so-
leus with cores was 80.6 ± 23.3 weeks (n = 11) vs. an average
age of 36.4 ± 32 weeks without cores (n = 5). Cores were
found in six out of the seven old (>97 weeks) Draggen soleus
muscles vs. zero out of four old WT.
The finding of cores in many (six/seven) old Draggen but
not WT soleus suggests that the reduced caffeine contracture
force in old Draggen is associated with acquired RyR1 dys-
function. The observation of cores in a 27-week-old animal
suggests that core formation may precede the reduction in
caffeine contracture force in Draggen muscle.
Apart from the structural core pathology described above,
there were no other overt myopathic or dystrophic changes,
and no significant mitochondrial pathology in the ageing WT
and Draggen mice.
Draggen skeletal muscle energy homeostasis is
impaired with age
Mouse models with acquired or genetic RyR1 dysfunction
have impaired ATP production34 as a result of depolarized
Figure 7 Evidence of impaired energy homeostasis in old Draggen muscle. (A) The body weights of WT (black square) and Draggen (empty circle) male
mice measured at weaning (3 weeks) and at time of terminal experiment (13–104 weeks). (B) Weight of dissected TA muscle at time of terminal ex-
periment in mice with and without access to a voluntary running wheel. Middle-aged wheel = voluntary running wheel added to cage when mice aged
51–57 weeks and TA muscle dissected and weighed after 9–18 weeks (WT, n = 6 muscles) or after 24 weeks (Draggen, n = 6 muscles). Old
wheel = voluntary running wheel added to the cage when mice aged 72–74 weeks and TA muscle was dissected and weighed after 25 weeks
(n = 6 muscles for WT and Draggen). (C) The adenylate energy performed after MVRCs and 30-Hz frequency ramp. **P < 0.01, ****P < 0.001.
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mitochondrial membranes.34,35 Male Draggen mice are
known to have increased energy expenditure compared with
their male WT littermates. They exhibit reduced body weight
due to fat loss, but muscle weight was conserved at ages up
to 54 weeks.14 The reduced body weight without significant
difference in muscle weight up to 54 weeks was confirmed
in our study (Figures 7A and S2).
However, if energy deficit increases with age, then the
weight difference between Draggen and WT mice should also
increase with age past 54 weeks. Consistent with this hypoth-
esis, the mean weight difference was greatest in old mice
(mean WT–mean Draggen weight was 0.8 g at weaning,
3.8 g between 9 and 30 weeks, 8.5 g between 38 and
79 weeks and 11.6 g between 95 and 104 weeks; Figure 7A).
Access to a voluntary running wheel from middle age has
been shown to prevent age-related loss of muscle mass in
WT mice.36 In keeping with these findings, the mean TA
weight for old WT males with access to a running wheel from
72 to 74 weeks of age for 25 weeks was 66 mg (± 2.7 SD, n = 6
TA muscles) vs. 56 mg (± 5.1 SD, n = 11, TA muscles) for age-
matched WT males without access to a running wheel
(P = 0.00002) (Figure 7B). In contrast, in old Draggen mice, ac-
cess to a voluntary running wheel from 71 weeks of age for
25 weeks led to a trend towards reduction in TA muscle
weight (Figure 7B). The mean TA weight of old Draggen mice
with access to a running wheel was 54 mg ± 2.5 SD (n = 6
muscles) vs. 57 mg ± 4.8SD (n = 19 muscles) for age-matched
Draggen mice without access to a wheel (Figure 7B; P = 0.09).
This suggests that exercise in old age may have exacerbated
the energy deficit of Draggen mice.
Activation of the catabolic or anabolic pathway is deter-
mined by the metabolic status of skeletal muscle. This is
reflected by the adenylate energy charge, which measures
the ratio of ATP to ADP and AMP. The energy charge per-
formed after MVRCs and 30-Hz frequency ramp stimulation
was significantly lower in old Draggen TA than either old
WT (P = 0.004) or middle-aged Draggen TA (P = 0.006) (Figure
7C). This indicates that the activity from MVRCs and 30-Hz
frequency ramp was enough to deplete ATP reserves in old
Draggen but not adult Draggen or old WT muscle.
Discussion
Our studies of changes in muscle function with age reveal
that muscle force becomes more resistant to potassium-
induced weakness in both old WT and Draggen mice. The
human age equivalents of the mouse age groups used are ap-
proximately 20–30, 43–50 and 65–70 years, respectively.37
Our data are consistent with the proposal that as muscle
ages, it develops mechanisms to maintain force despite
potassium-induced sodium channel inactivation and sarco-
lemmal depolarization. This suggests that the reduction in
attack severity observed in patients with PP may be part of
the phenotype shift observed in normal human ageing.
In contrast, the age-related muscle pathology was specific
to Draggen muscle, indicating that it is caused, or at least ac-
celerated by, chronic genetic ion channel dysfunction.
To our knowledge, this is the first time MVRCs have been
reported in rodents. As evidenced by the significant
differences in MVRC parameters from Draggen and WT TA
(Supporting Information), like human MVRCs,19–22 mouse
MVRCs can detect changes in skeletal muscle excitability
due to genetic ion channel dysfunction.
It was not technically possible to perform MVRCs in soleus.
However, the lack of significant change in mouse MVRCs with
age in either triceps or TA implies that increased resistance to
potassium-induced weakness is not due to universal changes
in baseline muscle excitability. The fact that decrement in am-
plitude of response after a train of 30 stimuli was similar
(Draggen TA, WT triceps) or even more pronounced (WT
TA) in old compared with young or middle-aged muscle sug-
gests that the maintenance of tetanic force in old muscle sub-
ject to the potassium-induced weakness assay is not due to a
resistance to potassium-induced sarcolemmal depolarization.
Variation in extracellular K+, Cl and Na+ cannot underlie the
increased resistance of old muscle to potassium-induced
weakness as extracellular ionic concentrations were constant.
Therefore, the data are consistent with old muscle develop-
ing intrinsic mechanisms to maintain force, despite normal
(or for old WT TA apparently increased) sodium channel
inactivation and sarcolemmal depolarization.
The exact mechanism for the apparent resistance to
potassium-induced weakness with age remains to be deter-
mined. Our data suggest that force and excitability can be
differentially regulated in old muscle and more specifically
that reduced excitability may not translate into the expected
reduction in force. Reviewing the literature on PP, previous
studies have also provided evidence that force and excitabil-
ity can be dissociated.38–42 In isolated human myofibres from
a patient with HyperPP, reduction of pH restored force but
not resting membrane potential during potassium-induced
weakness.38 In the HypoPP mouse models, acetazolamide
was effective at preventing CMAP decrement, but did not
prevent loss of muscle force during induced attacks.39,40 In
humans with HypoPP, action potential initiation and propaga-
tion failed after muscle twitch tension during an induced
attack of paralysis,42 and in another study, the patient had
regained sufficient muscle strength to flex their arm against
gravity before direct electrical stimulation could elicit a mus-
cle twitch.41 How force is maintained despite a depolarized
resting membrane potential as observed in the Hyper PP
muscle fibres, and why the maintenance of CMAP does not
translate into maintenance of force in mice or humans with
Hypo PP, remains unclear but may shed light on how healthy
and PP old muscle can maintain tetanic force despite
depolarization.
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Baseline soleus tetanic force of Draggen mice showed sig-
nificant decline with age (P= 0.03). The intercept (P = 0.006),
but not the slope of a linear fit to force-age data was differ-
ent between Draggen and WT mice, suggesting lower base-
line ex vivo tetanic force in Draggen mice (Figure 2E). A
lower baseline force for Draggen muscle was not detected
in grip strength experiments in vivo, but grip strength did de-
cline in Draggen mice after 60 weeks of age.14 As the baseline
force decline was not detected in vivo, it is possible that the
reduced baseline force in Draggen may be the result of in-
creased sensitivity of Draggen muscle to the ex vivo condi-
tions. A depolarization of resting membrane potential by
approximately 20 mV has been reported when comparing
the same mouse muscle resting membrane potential mea-
sured in vivo or in situ vs. ex vivo.43 As our MVRC data (see
Supporting Information) suggest that Draggen muscle is
relatively depolarized compared with WT muscle in vivo, an
additional depolarization of this scale would potentially have
a disproportionate effect on Draggen, compared with WT
muscle force measured ex vivo.
Old age in Draggen muscle was associated with reduced
caffeine contracture force (Figure 5A), decreased energy
charge (Figure 7D) and structural core pathology (Figures 6
and 8). Pathogenic mutations in at least eight genes have
been associated with core myopathies in humans and occur
most frequently due to mutations in RYR1, TTN and
MYH7.27 Core-like regions have also been reported in mouse
models with impaired ATP production secondary to RyR1
mutation.34 Thus, acquired RyR1 dysfunction seems the most
likely cause for the reduced caffeine contracture force,
decreased energy charge and the structural core pathology
observed in aged Draggen muscle (Figure 8).
Acquired RyR1 dysfunction resulting in Ca2+ leak and con-
sequent SR Ca2+ store depletion has been reported in normal
aged mouse and human muscle.31,32,35,44 In these studies, SR
calcium concentration and release rather than caffeine con-
tracture were measured. This difference in technique may ex-
plain why we failed to see any significant deficit in WT muscle
caffeine contracture. However, given these observations in
normal ageing, it seems likely that fixed progressive weak-
ness in Draggen mice represents a form of accelerated ageing
rather than a process specific to Draggen muscle.
Pertinent to these observations are conclusions from a
detailed time course study of molecular changes across the
life span in rats for various ageing tissue45 that showed the
most prominent common pathway downregulated with age-
ing was related to mitochondrial oxidative phosphorylation
and respiratory electron transport (in skeletal muscle, liver
Figure 8 Aged Draggen muscle. In aged Draggen muscle, we found no evidence of a change in baseline muscle excitability with age (MVRCs and fre-
quency ramp). However, caffeine contracture force and energy charge were significantly lower in old Draggen muscle, and core-like regions were found
in old Draggen but not WT muscle. Taken together, our data suggest that progressive acquired RyR1 dysfunction and associated impairment of ener-
getic homeostasis are responsible for the fixed weakness in old Draggen mice.
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and kidney), consistent with the proposal that the mitochon-
dria become less competent with age, depriving cells of
critical supplies of ATP. Calcium release through RyR1 is
known to stimulate mitochondrial ATP production.46 Thus,
in normal ageing, the combination of impaired calcium re-
lease reducing the stimulus for mitochondrial ATP production
and decreased mitochondrial oxidative capacity with age
could form a double hit for ageing skeletal muscle. This would
be expected to manifest earlier in male Draggen mice be-
cause of their increased energy requirements.14 As exercise
would exacerbate this energy deficit by increasing energy
requirement further, the observation that old Draggen mice
were unable to mount an anabolic response to exercise is
in keeping with this hypothesis (Figure 7D).
This study reinforces the close links between membrane ex-
citability, RyR1 and mitochondrial function (Figures 1 and 8).
The interconnected nature of RyR1 and mitochondrial func-
tion with membrane excitability is apparent in both humans
and mice as evidenced by reports of humans with RyR1
mutations47 and mitochondrial DNA mutations48 that have a
PP-like phenotype; a patient with PP due to mutation in
NaV1.4 that responds to treatment with coenzyme Q1049
and mice with an RyR1 mutation and core-like regions on
muscle biopsy that exhibit potassium responsive weakness
similar to PP.34
One of the limitations of this study is that we did not mea-
sure the frequency of spontaneous attacks in Draggen mice
and therefore cannot comment on whether reduction in
the severity of potassium-induced weakness is associated
with a reduction in the frequency of spontaneous attacks.
In addition, we limited the study to male mice because, as
for humans with the condition, some female carriers are
asymptomatic.14,50 It is not known if a gender difference in
the PP phenotype change with age exists, and so, future work
should confirm that a similar phenomenon is observed in
females and is associated with the same pathophysiology.
Finally, as discussed in the methods, for technical reasons,
we could not perform MVRCs on soleus nor the potassium-
induced weakness assay on TA. It is therefore possible that
the resistance to potassium-induced weakness with age is
limited to soleus (composed mainly of oxidative fibres) and
impairment of energy homeostasis to TA (composed mainly
of glycolytic fibres),15 especially as there are complex effects
of ageing on myofibre-type differences in contractile and
metabolic properties. This impact of myofibre type could be
tested by using the fast twitch glycolytic extensor digitorum
longus muscle (~90% Types 2X and 2A15) to measure changes
in potassium-induced weakness with age. However, as human
muscles are predominantly oxidative and have been reported
to be most similar to soleus transcriptomically,16 from a
translational point of view, the value of this may be limited.
Moreover, although energy charge and the effect of exercise
on muscle weight were only measured in TA, the observa-
tions of reduced caffeine contracture force combined
with core-like structures in aged Draggen soleus provide in-
dependent evidence to suggest that oxidative phosphoryla-
tion is impaired.34,35,46
An increased energy expenditure and/or deficit in body
weight has not, to our knowledge, been reported in humans
with PP. However, PP is a rare disease, and it is likely that un-
less specifically looked for subtle difference in body weight
may have been missed. A decrease in the ATP to ADP ratio
has been observed for patients with myotonic dystrophy
and associated with a small but significant reduction in mito-
chondrial function.51 This suggests that the increased ener-
getic requirement of ion channel dysfunction may also
affect human muscle but may not be associated with clear
weight discrepancies. Like the study in myotonic dystrophy,
magnetic resonance spectroscopy could be used to confirm
an ATP deficit in older humans with PP. If present, muscle bi-
opsies to specifically look for core pathology should be con-
sidered. Structural pathology consistent with cores in our
opinion (originally reported as target lesions) has been re-
ported in one kindred with normokalaemic PP, which is be-
lieved to be within the spectrum of HyperPP.52,53 However,
they have not been a common finding in PP. In this case,
the gastrocnemius was biopsied, and the biopsy was taken af-
ter a very prolonged attack after which the patient had not
fully recovered force.53 Gastrocnemius is one of the most
commonly and severely affected muscles on MRI of HyperPP
patients.54 However, our clinical practice, as for many other
centres in Europe and the United States, is to perform biop-
sies of quadriceps, deltoids or biceps. This, along with the fact
that patients tend to be biopsied early in the course of the
disease, may explain why cores have not to date been a
prominent feature reported for PP patients.
In summary, our data demonstrate that phenotype transi-
tion with age also occurs in the Draggen mouse model of
HyperPP. Though intrinsic muscle ageing protects against
potassium-induced weakness in Draggen mice, it is also asso-
ciated with impaired SR Ca2+ release, a process that seems to
be accelerated in Draggen muscle. Thus, ageing can modify
the clinical effect of genetic mutation. In conclusion, this
work provides a replicable example of how studying pheno-
type change with age in monogenic disease can yield novel
insight into both disease physiology and the ageing process
itself.
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Figure S1. Experimental setup for MVRCs in mouse muscle. a.
Experimental set up for TA b. Experimental set up for triceps.
In both A and B a monopolar stimulating needle electrode
(28G TECA, Viasys Healthcare Madison, Wisconsin) was
inserted into the distal muscle. A reference anode was
inserted slightly above and lateral to the monopolar stimulat-
ing electrode. The reference anode consisted of a 27G hollow
bore disposable steel needle attached to reference anode
lead with crocodile clip. Stimuli consisting of 0.05 ms rectan-
gular current pulses were delivered. Muscle activity was re-
corded with a concentric needle electrode (disposable 30G
concentric EMG needle, TECA) inserted into the proximal
end of the muscle. A ground electrode was inserted under
the skin in the axilla. The ground electrode consisted of a
27G hollow bore disposable steel needle that was bent to
make it easier to insert under the skin and attached to croc-
odile clip on the ground cable.
Figure S2.Weight of dissected soleus muscle at time of termi-
nal experiment in mice without access to a voluntary running
wheel.
Data S1. Supporting Information
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